RA CAPITAL MANAGEMENT, L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001346824

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2023 · 66 positions · Total reported value $5.08B · Top-10 concentration 55.1% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 38.4% · 15 new · 12 cut · 11 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -13.6% · vs SPY -15.8% · Prev Value $11.51B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -1.6% · vs SPY -3.7% · Latest Value $9.72B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2023 13F filing, RA CAPITAL MANAGEMENT, L.P. disclosed 66 equity positions with a combined reported value of $5.08B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 55.1% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2023 were ASND ($1.00B), LEGN ($420.80M), PCVX ($402.30M). By sector, the heaviest allocations are Health Care 74.2%, Consumer Discretionary 1.5%.

Versus the prior quarter, RA CAPITAL MANAGEMENT, L.P. opened 15 new positions, trimmed 12 and fully exited 11, a turnover rate of 38.4% of positions.

The largest new positions opened in Q3 2023 were ASND ($1.00B), LEGN ($420.80M), PCVX ($402.30M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2023)

  • ASND ASCENDIS PHARMA A/S · $1.00B
  • LEGN LEGEND BIOTECH CORP · $420.80M
  • PCVX VAXCYTE INC · $402.30M
  • IMGN IMMUNOGEN INC · $211.42M
  • ETNB 89BIO INC · $176.28M
  • BIIB BIOGEN INC · $136.96M
  • RYTM RHYTHM PHARMACEUTICALS INC · $130.12M
  • AVTE AEROVATE THERAPEUTICS INC · $112.14M

Fully Exited (vs previous quarter)

No tracked position was fully exited this quarter.

Insider Transactions (Form 4)

Latest RA CAPITAL MANAGEMENT, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-02 Buy Bambusa Therapeutics, Inc. 164,891 $16.00 SEC filing
2026-11-02 Buy Bambusa Therapeutics, Inc. 2,335,109 $16.00 SEC filing
2026-11-02 Conversion Bambusa Therapeutics, Inc. 1,331,080 — SEC filing
2026-11-02 Conversion Bambusa Therapeutics, Inc. 3,144,858 — SEC filing
2026-10-30 Buy Bambusa Therapeutics, Inc. 263,911 $14.92 SEC filing
2026-10-30 Buy Bambusa Therapeutics, Inc. 189,909 $14.23 SEC filing
2026-10-29 Sell LENZ Therapeutics, Inc. 107,170 $3.36 SEC filing
2026-10-29 Sell LENZ Therapeutics, Inc. 451,998 $3.36 SEC filing

All insider transactions →

Fund Profile

RA Capital Management is a Boston-based investment firm founded by Peter Kiernan, specializing in healthcare-focused investments with a long-term, value-oriented approach.

Investment Approach

Focuses on healthcare sector investments

Long-term, value-oriented strategy

Deep fundamental research and analysis

Asset Classes & Strategy

Primarily invests in public equities

Also manages private investments in healthcare companies

Concentrated portfolio approach with significant positions in healthcare companies

Key Personnel

Peter Kiernan: Founder and portfolio manager

Team of experienced investment professionals with healthcare expertise

Notable Facts

Founded in 2002

Manages approximately $16.4 billion in assets

Files SEC Form 13F for US equity positions

This profile is based on publicly available information and should not be considered as official disclosure from the firm.

Sector Allocation

Health Care 74.2%
Materials 0.0%
Other 23.1%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 10.72M $1.00B 19.76%
19.76%
New
2 6.26M $420.80M 8.28%
8.28%
New
3 7.89M $402.30M 7.92%
7.92%
New
4 13.32M $211.42M 4.16%
4.16%
New
5 11.42M $176.28M 3.47%
3.47%
New
6 532.89K $136.96M 2.70%
2.70%
New
7 5.68M $130.12M 2.56%
2.56%
New
8 8.26M $112.14M 2.21%
2.21%
New
9 6.94M $103.48M 2.04%
2.04%
New
10 6.32M $102.98M 2.03%
2.03%
New
11 7.24M $99.65M 1.96%
1.96%
New
12 17.20M $98.91M 1.95%
Form 4 · 1 →
1.95%
New
13 46.20M $97.95M 1.93%
1.93%
New
14 7.81M $95.83M 1.89%
1.89%
New
15 9.17M $92.39M 1.82%
1.82%
New
16 5.55M $89.26M 1.76%
1.76%
New
17 4.72M $86.69M 1.71%
1.71%
New
18 3.05M $85.14M 1.68%
1.68%
New
19 9.00M $83.25M 1.64%
1.64%
New
20 2.74M $74.52M 1.47%
1.47%
New
21 10.60M $72.43M 1.43%
1.43%
New
22 1.00M $69.89M 1.38%
1.38%
New
23 6.42M $62.56M 1.23%
1.23%
New
24 14.93M $61.97M 1.22%
1.22%
New
25 18.47M $58.37M 1.15%
1.15%
New
26 5.59M $56.15M 1.10%
1.10%
New
27 4.69M $53.71M 1.06%
1.06%
New
28 4.16M $53.00M 1.04%
1.04%
New
29 11.61M $51.55M 1.01%
1.01%
New
30 4.42M $48.37M 0.95%
0.95%
New
31 22.75M $48.23M 0.95%
Form 4 · 1 →
0.95%
New
32 5.96M $46.22M 0.91%
0.91%
New
33 4.81M $45.99M 0.91%
0.91%
New
34 1.98M $42.13M 0.83%
0.83%
New
35 8.13M $41.31M 0.81%
0.81%
New
36 6.42M $40.94M 0.81%
0.81%
New
37 6.81M $37.59M 0.74%
0.74%
New
38 1.24M $36.56M 0.72%
0.72%
New
39 9.46M $35.76M 0.70%
0.70%
New
40 13.15M $34.59M 0.68%
Form 4 · 4 →
0.68%
New
41 2.01M $30.80M 0.61%
0.61%
New
42 1.76M $30.55M 0.60%
0.60%
New
43 3.18M $30.23M 0.59%
0.59%
New
44 4.40M $30.13M 0.59%
0.59%
New
45 204.50K $29.87M 0.59%
0.59%
New
46 2.12M $28.99M 0.57%
0.57%
New
47 3.37M $26.93M 0.53%
0.53%
New
48 1.48M $20.79M 0.41%
0.41%
New
49 6.72M $17.13M 0.34%
0.34%
New
50 800.00K $16.07M 0.32%
0.32%
New

FAQ

What did RA CAPITAL MANAGEMENT, L.P. buy in 2023-Q3?

In its 2023-Q3 13F filing, RA CAPITAL MANAGEMENT, L.P. reported 66 equity positions worth $5.08B in aggregate; its largest disclosed positions were ASND ($1.00B), LEGN ($420.80M), PCVX ($402.30M).

How large is RA CAPITAL MANAGEMENT, L.P.'s portfolio?

RA CAPITAL MANAGEMENT, L.P. reported $5.08B of long equity holdings across 66 positions as of 2023-Q3. Top-10 holdings account for 55.1% of reported value.

What is RA CAPITAL MANAGEMENT, L.P.'s investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/ra-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →